MedTrace Logo

Immune Mechanisms of Rejection in Human Lung Allografts

NCT00861900 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 778

Last updated 2018-06-19

No results posted yet for this study

Summary

The investigators have obtained compelling evidence that the development of anti-human leukocyte antigen (anti-HLA) antibodies against mismatched donor antigens significantly correlates with the development of bronchiolitis obliterans (BOS). Further, these anti-HLA antibodies are developed at least 15 months prior to any clinical evidence of BOS. This lag period between the development of anti-HLA antibodies and the onset of BOS gives us an opportunity to intervene to delay and/or prevent the development of BOS.

Conditions

  • Bronchiolitis Obliterans

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Thalachallour Mohanakumar, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Primary Completion
2017-07-31
Completion
2017-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00861900 on ClinicalTrials.gov